October 2015, Vol. 4, No. 5
Genetic Counseling in Personalizing Care: A New Department in PMOLetter to Our Readers
I am pleased to announce a new department in PMO, Genetic Counseling. In each issue, PMO editorial board member Cristi Radford, MS, CGC, of the Moffitt Cancer Center will contribute an impactful article. In this issue, you will read about BRCA1/2 testing for any patient with pancreatic adenocarcinoma. If you have an intriguing case to share, I encourage you to submit it to our Editorial Director at Ksiyahian@the-lynx-group.com.
The mission of our journal is to provide a bridge between academic research and practicing clinicians by demonstrating the immediate implications of precision medicine—including advances in molecular sequencing, targeted therapies, and new diagnostic modalities—to the management of patients with cancer, offering oncologists, oncology nurses, payers, researchers, drug developers, policymakers, and all oncology stakeholders the relevant practical information they need to improve cancer outcomes. Improved outcomes lie in the ability to administer effective therapies. Our ability to prescribe effective therapies has more and more become reliant on our understanding of the molecular biology of the tumor microenvironment as well as the genomic and genetic information of the patient.
To this end, this month we offer an intriguing interview with Nazneen Aziz, PhD, of the Phoenix Children’s Hospital revealing how genetic, genomic, and biomarker information is being put to work to improve outcomes for patients. We also present a case study on molecular pathways in non–small cell lung cancer as well as several other relevant articles on the personalized approach to caring for patients with cancer.
As always, thank you for your loyal readership. We hope the addition of the genetic counseling department will be of value to you in your practice.
Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology
Increasingly, genomic alterations are being recognized and targeted for clinical trials. Improving clinical trial accrual in this environment may require multiple histology basket trials that increase the percentage of patients with “actionable” alterations, said Funda Meric-Bernstam, MD, at PMO Live 2015. The implications for the use of predictive markers for [ Read More ]
Despite the promise of molecular profiling, approximately 80% of patients with lung cancer lack a defined genotypic mutation and thus become resistant when treated with a tyrosine kinase inhibitor. According to data presented at the congress, however, lung cancer remains a highly mutated disease, suggesting great potential for immunotherapy. “If [ Read More ]